Shopping Cart
Remove All
Your shopping cart is currently empty
Rilotumumab
😃Good
Catalog No. T76758Cas No. 872514-65-3
Alias AMG 102
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (CRPC) and gastric cancer.
Rilotumumab
Rilotumumab
😃Good
Catalog No. T76758Alias AMG 102Cas No. 872514-65-3
Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (CRPC) and gastric cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $255 | In Stock | In Stock | |
| 5 mg | $668 | In Stock | In Stock | |
| 10 mg | $1,070 | - | In Stock | |
| 25 mg | $1,580 | - | In Stock | |
| 50 mg | $2,130 | - | In Stock | |
| 100 mg | $2,880 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:97.51% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (CRPC) and gastric cancer. |
| In vitro | In an overnight treatment at 10 μg/mL, Rilotumumab induces a decrease in MET phosphorylation at Y1234 and Y1235, accompanied by an increase in total MET[2]. |
| In vivo | In vivo, treatment with Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once every two days; for 11 days) inhibits glioma cell growth[2]. |
| Synonyms | AMG 102 |
| Reactivity | Human |
| Verified Activity | Immobilized Human HGF Protein (His) at 2 μg/mL (30 μL/well) can bind Rilotumumab. The EC50 is 25.07 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | HGF/SF |
| Molecular Weight | 145.2 kDa |
| Cas No. | 872514-65-3 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Rilotumumab | purchase Rilotumumab | Rilotumumab cost | order Rilotumumab | Rilotumumab in vivo | Rilotumumab in vitro | Rilotumumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.